Format
Items per page
Sort by

Send to:

Choose Destination

Results: 6

1.

Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents.

Elbayoumi TA, Pabba S, Roby A, Torchilin VP.

J Liposome Res. 2007;17(1):1-14.

PMID:
17454399
[PubMed - indexed for MEDLINE]
2.

Negatively charged polymers protect antinuclear antibody against inactivation by acylating agents.

Samokhin GP, Mongayt DA, Iakoubov LZ, Levchenko TS, Torchilin VP.

Anal Biochem. 2001 May 15;292(2):245-9.

PMID:
11355857
[PubMed - indexed for MEDLINE]
3.

The prognostic significance of autoantibodies against dsDNA in patients with colorectal adenocarcinoma.

Syrigos KN, Charalambopoulos A, Pliarchopoulou K, Varsamidakis N, Machairas A, Mandrekas D.

Anticancer Res. 2000 Nov-Dec;20(6B):4351-3.

PMID:
11205270
[PubMed - indexed for MEDLINE]
4.

Antineural and antinuclear autoantibodies are of prognostic relevance in non-small cell lung cancer.

Blaes F, Klotz M, Huwer H, Straub U, Kalweit G, Schimrigk K, Schäfers HJ.

Ann Thorac Surg. 2000 Jan;69(1):254-8.

PMID:
10654525
[PubMed - indexed for MEDLINE]
5.

Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies.

Iakoubov LZ, Torchilin VP.

Cancer Detect Prev. 1998;22(5):470-5.

PMID:
9727629
[PubMed - indexed for MEDLINE]
6.

A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice.

Iakoubov LZ, Torchilin VP.

Oncol Res. 1997;9(8):439-46.

PMID:
9436197
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk